Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Cytomx Thera (CTMX)

Cytomx Thera (CTMX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 249,887
  • Shares Outstanding, K 45,434
  • Annual Sales, $ 59,500 K
  • Annual Income, $ -84,600 K
  • 60-Month Beta 0.64
  • Price/Sales 4.27
  • Price/Cash Flow N/A
  • Price/Book 2.75

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.55
  • Number of Estimates 5
  • High Estimate -0.29
  • Low Estimate -0.84
  • Prior Year -0.72
  • Growth Rate Est. (year over year) +23.61%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.28 +0.47%
on 11/08/19
7.33 -27.63%
on 10/18/19
-1.81 (-25.39%)
since 10/11/19
3-Month
5.28 +0.47%
on 11/08/19
9.96 -46.74%
on 09/11/19
-4.32 (-44.85%)
since 08/13/19
52-Week
5.28 +0.47%
on 11/08/19
19.75 -73.14%
on 02/05/19
-8.95 (-62.80%)
since 11/13/18

Most Recent Stories

More News
CytomX Therapeutics to Present at Upcoming Healthcare Conferences

CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody(TM) therapeutic...

CTMX : 5.30 (-3.55%)
CytomX Therapeutics Announces Third Quarter 2019 Financial Results and Provides Business Update

CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody(TM) therapeutic...

CTMX : 5.30 (-3.55%)
CytomX Therapeutics Announces Initiation of Phase 2 Clinical Trial Evaluating the Anti-PD-L1 Probody CX-072 in Combination with YERVOY(R) in Patients with Relapsed or Refractory Melanoma

CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody(TM) therapeutic...

CTMX : 5.30 (-3.55%)
CytomX Therapeutics to Announce Third Quarter 2019 Financial Results

CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody(TM) therapeutic...

CTMX : 5.30 (-3.55%)
CytomX Therapeutics Announces New Employment Inducement Grants

CytomX Therapeutics, Inc. (NASDAQ:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody(TM) therapeutic...

CTMX : 5.30 (-3.55%)
CytomX Therapeutics Announces Appointment of Amy C. Peterson, M.D. as Chief Development Officer

-Industry Veteran Joins to Advance Maturing Platform and Pipeline to Next Phase of Development-

CTMX : 5.30 (-3.55%)
CytomX Therapeutics to Present at Upcoming Healthcare Conferences

CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody(TM) therapeutic...

CTMX : 5.30 (-3.55%)
Cytomx Therapeut Set to Possibly Rebound After Yesterday's Selloff of 2.49%

Cytomx Therapeut (NASDAQ:CTMX) traded in a range yesterday that spanned from a low of $8.52 to a high of $8.90. Yesterday, the shares fell 2.5%, which took the trading range below the 3-day low of $8.78...

CTMX : 5.30 (-3.55%)
CytomX Therapeutics (CTMX) Reports Q2 Loss, Lags Revenue Estimates

CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -16.36% and -40.34%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

CTMX : 5.30 (-3.55%)
CytomX Therapeutics Announces Second Quarter 2019 Financial Results and Provides Business Update

CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody(TM) therapeutic...

CTMX : 5.30 (-3.55%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade CTMX with:

Business Summary

CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered...

See More

Key Turning Points

2nd Resistance Point 5.67
1st Resistance Point 5.49
Last Price 5.30
1st Support Level 5.21
2nd Support Level 5.12

See More

52-Week High 19.75
Fibonacci 61.8% 14.22
Fibonacci 50% 12.52
Fibonacci 38.2% 10.81
Last Price 5.30
52-Week Low 5.28

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar